Skip to main content
. 2023 Mar 22;81(2):146–154. doi: 10.1055/s-0043-1761433

Table 2. Neurological symptoms of hospitalized patients with COVID-19.

OD
Overall without with p - value
(N = 100) (N = 56) (N = 44)
Delay, days 1 1.48 ± 3.41 1.39 ± 3.48 1.55 ± 3.39 0.84
Neurological symptom, % 80 64.3 100 <0.001
Ageusia/hypogeusia 2 50 12.5 97.7 <0.001
Vision impairment 11 8.9 13.6 0.45
Dizziness 3 24 16.1 34.1 0.03
Irritability 12 7.1 18.2 0.09
Impaired consciousness 4 18 23.2 11.4 0.12
Confusion 9 8.9 9.1 0.97
Muscle weakness 5 2 1.8 2.3 1
Myalgia 31 23.2 40.9 0.05
Headache 16 12.5 20.5 0.28
Orthostatic intolerance 6 49 37.5 63.6 0.01
Frequency
 Never 51 62.5 36.4* 0.02
 Rarely 14 12.5 15.9
 Occasionally 19 17.9 20.5
 Frequently 15 7.1 25*
 Almost always 1 0 2.3
Intensity 0.01
 None 51 62.5* 36.4*
 Mild 23 23.2 22.7
 Moderate 20 12.5 29.5*
 Severe 6 1.8* 11.4* 0.03
Xerophthalmia 7 20 12.5 29.5 0.03
Xerostomia 71 64.3 79.5 0.09
COMPASS-31 TWS (0–100) 16.69 ± 11.52 12.92 ± 13.72 20.90 ± 23.47 0.002
TWS minus GI (0–75) 13.82 ± 9.71 10.58 ± 12.16 17.21 ± 20.26 0.003

Abbreviations: COMPASS-31, Composite Autonomic Symptom Score 31; TWS, total weighted score; () or parenthesis, maximum possible score; GI, gastrointestinal; CI, confidence interval; OD, olfactory disfunction. Notes: Values expressed as the mean ± standard deviation or percentage (%). Bold numbers indicate statistical significance. * p- value < 0.05. Categorical variables analysis performed by the Pearson chi-squared or Fisher exact tests. Continuous variables and odds ratio analysis performed by generalized linear model within the groups without and with OD. Olfactory dysfunction = subjective anosmia/hyposmia. 1 Onset of illness to manifestation. 2 OR = 301, 95%CI 35.59 to 2,545.42. 3 OR = 2.70, 95%CI 1.04 to 6.96. 4 Syncope, seizure, daytime sleepiness, insomnia. 5 Due to acute cerebrovascular disease. 6 OR = 2.91, 95%CI 1.28 to 6.61. 7 OR = 2.93, 95%CI 1.05 to 8.16.